ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,339.23
-0.37%
Dow Jones
39,086.80
-1.47%
Gold vs US Dollar
2,336.115
-1.92%
Brent Oil
80.805
-0.89%
Bitcoin
67,230.82
-2.71%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. ImmunityBio Inc (IBRX) Share Price

IBRX ImmunityBio Inc

6.653
-0.287 (-4.14%)
Last Updated: 18:52:53
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 ImmunityBio Inc NASDAQ:IBRX NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.287 -4.14 6.653 6.65 6.66 6.93 6.61 6.89 1,577,626 17:52:53   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 622k -583.2M -0.8734 -37.20 21.69B
 Type  Size  Price  Time  Units 
 9 50 6.65 17:52:53 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore IBRX News
17/05/202414:00BWConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
09/05/202422:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/05/202413:00BWImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
02/05/202421:04BWImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
30/04/202413:00BWImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
25/04/202405:03BWImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
23/04/202402:56BWImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Period
Draw mode
Data Downloads for IBRX

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest ImmunityBio Inc Articles